NOW ENROLLING

Psoriatic Arthritis Clinical Trial Opportunity

If you have been diagnosed with psoriatic arthritis and medication has not fully improved your symptoms, then you may qualify for our research study.

See If You Qualify
Para español oprima aquí

THE KEY TO THE FUTURE IS YOU

Psoriatic arthritis is a chronic inflammatory condition that can affect those with psoriasis who also develop joint pain. Only about 15 percent of those with psoriasis develop this arthritis.

There are many medications available to those who have psoriatic arthritis, most of which aim to reduce inflammation and pain. Some may even slow the progress of the condition by preserving the bone around the joints. Additionally, there are medications targeted at the immune system itself.


Unfortunately up to about 40 percent of psoriatic arthritis patients may not achieve meaningful improvement of their symptoms with current medication options. Patients who qualify for this study will receive guselkumab (Tremfya). This drug has already been proven to be effective for Psoriatic Arthritis at other dose regimens. The study is intended to provide additional data on the impact of guselkumab (Tremfya).

Spots Are Limited - See If You Qualify to Participate

How the SOLSTICE Study Works

—

This research study called SOLSTICE seeks to learn more about the effectiveness of Guselkumab (Tremfya) in patients diagnosed with psoriatic arthritis who have not achieved adequate improvement of their symptoms when using other treatments.

The length of this study is 1 year with the opportunity to take part in a second full year if a subject successfully completes year 1.

Patients who fit the qualifications will be placed in one of two groups randomly. Participants will only be in these groups for the first 24 weeks of the study.

One group will receive Guselkumab (Tremfya), and the other will receive a placebo. A placebo looks like the real drug, but it has no active ingredients. Study participants and study staff will not know who is receiving the placebo or who is receiving the drug. 

At week 24 all participants will receive the real medication, Tremfya, for the remainder of the study. The study will require appointments with the research clinic every 4 weeks.

Each appointment will feature health checkups and questions related to your daily life with psoriatic arthritis. Various activities, such as blood draws and EKGs may also be required at study appointments.

Note: participation in this study requires frequent visits to our clinic in The Woodlands. We recommend interested patients be located in Houston or the surrounding area.

Do You Qualify?

Not everyone with psoriatic arthritis will qualify for this study. There are specific criteria patients must meet. Here is a list of the most basic criteria:

  • 18 years or older
  • Must have a diagnosis of Psoriatic Arthritis from a Rheumatologist.
  • Currently have swollen or tender joints
  • You now have at least 1 patch of psoriasis on your skin or your nails
  • Must have a history of inadequate response and/or intolerance to ONE anti-TNF therapy, such as: Enbrel, Remicade, Humira, Cimzia or Simponi. (If you have taken more than one of these drugs in the past, you would not be eligible for enrollment in this study).
  • No prior use of Tremfya, Stelara, Cosentyx, Taltz, Siliq, Skyrizi, Xeljanz, Rinvoq, or Olumiant. 
  • You cannot have a diagnosis of Fibromyalgia or Rheumatoid Arthritis.

You may fit all of these eligibility requirements, but some additional criteria may make you ineligible.

JOIN THE EFFORT FOR BETTER PSA TREATMENT

Learn If You Qualify

Click the button below or call us at (281) 766-7886

Contact Us